Today's Rundown Merck buys Calporta for preclinical neurodegeneration assets Merck to slash more than 100 R&D jobs from French site Genfit CEO Pascal Prigent on better NASH tests for R&D and the doctor’s office Kiadis dumps phase 3 drug, halves head count in pivot to NK cells Weill Family Foundation gifts $106M for public-private 'Neurohub' Exact Sciences nets FDA breakthrough designation for liver cancer blood test Pfizer's Upjohn and Mylan will become Viatris. Wait, haven't we heard that name before? Featured Story | | | Wednesday, November 13, 2019 Merck has struck a deal to buy Calporta Therapeutics for up to $576 million. The takeover centers on TRPML1 agonists designed to treat neurodegenerative disorders by clearing toxic proteins from the brain. |
|
|---|
|
Top Stories Wednesday, November 13, 2019 While Merck announced it was spending a few hundred million on an early-stage biotech this morning, now it is now shuttering an R&D site in Riom in the heart of France. Wednesday, November 13, 2019 What the NASH field needs, says Genfit CEO Pascal Prigent, is something like Hb1Ac for diabetes: a test that’s easy to do and that’s “commonly regarded as the right way to monitor the disease that everybody can use.” Genfit is working on a blood test that could become the first diagnostic approved specifically for NASH. Wednesday, November 13, 2019 Kiadis has dropped its lead program midway through a phase 3 trial. The action will see Kiadis lay off half of its staff and switch its attention to earlier-stage natural killer cell therapies against solid tumors and hematological cancers. Wednesday, November 13, 2019 The Weill Family Foundation is stumping up $106 million to create a so-called “Neurohub” that aims to unite the University of California, San Francisco, UC Berkeley and the University of Washington in an effort to seek out new treatments for brain diseases. Wednesday, November 13, 2019 Exact Sciences announced it received a breakthrough device designation from the FDA for its blood-based test for liver cancer alongside new data demonstrating its sensitivity for early-stage disease. Tuesday, November 12, 2019 Finding the perfect name is no easy task for a new company, particularly in the exotic world of biopharma monikers. Mylan and Pfizer's Upjohn business, working to close their generics megamerger, believe they have one that strikes the right tone—even if that name is very familiar to one of the partners. Enrollment Showcase Resources Sponsored by: Veeva Systems Medical Affairs 2025 brings together leading perspectives from AstraZeneca, Bristol-Myers Squibb, Merck, Lilly, and other innovative life sciences organizations on key challenges impacting medical affairs and a roadmap for success in the coming decade. Sponsored by: SHYFT Analytics This whitepaper provides a snapshot of where the biopharma industry is now, where it's heading, and how companies are allocating their resources to adapt & grow. Sponsored by: IBM Watson Health IBM’s highlighted solutions reside in a security-rich cloud environment—home for capturing, managing and analyzing clinical study data with control, accuracy and confidence. These solutions lay the groundwork for further integration with IBM® Watson® cognitive technology. Sponsored by: IBM Watson Health Inpatient View and Outpatient View are powered by robust data assets and use sophisticated projection methodologies to help ensure accuracy of reporting. Sponsored by: IBM Watson Health Acknowledging various stakeholder networks, as well as recognizing variances within the regulatory environment, we believe, is essential for companies looking to uncover the right decision-makers in support of biologics or biosimilars. Learn more. Sponsored by: ON24 Discover solutions to the most common challenges faced by medical device companies. Sponsored by: Eli Lilly and Company in partnership with Xcenda Download this complimentary paper that explores the practice of step therapy and its impact on key stakeholders in the US healthcare system. Sponsored by: Clarivate Analytics 18 high-value new licensing deals worth in excess of $500 million took place during the second quarter of 2019 -Get the Q2 2019 Biopharma licensing report for full details and insights. Sponsored by: Patheon, by Thermo Fisher Scientific Is your API development on track? Sponsored by: BBK Worldwide Get the latest data on how people are using apps to manage their health, and learn how you can leverage it in the development of your next clinical trial app. Sponsored by: Blue Latitude Health Report: How to design digital services that deliver value and improve outcomes for patients, healthcare professionals and the healthcare systems they serve Sponsored by: Article Galaxy powered by Reprints Desk This white paper examines the skyrocketing cost of drug development and provides step-by-step guidance for executing a successful fail fast strategy. Sponsored by: Outer Edge Technology Companies that don’t have a cloud strategy are at a competitive disadvantage. Why? The cloud has a measurable impact on business. Sponsored by: Roche and IQVIA A global landscape study of funding trends and innovations. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. Advanced Therapies: Immunotherapies, Cell Therapies and Gene Therapies November 15, 2019 | Boston, MA Countdown to Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register Now at www.drugstomarket.com/drugbootcamp and start Pre-Boot Camp Preparation A Rare Affair for Rare Diseases January 12, 2020 | San Francisco, CA | 